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ABSTRACT 
Introduction. In the current edition, Szejko and colleagues describe a subset of patients with Gilles de la Tourette syndrome 
(GTS) who had dystonic tics (DTs), which occurred more frequently in those with a greater number of tics and likely contribute 
to impairment.
Clinical reflections. DTs manifest as an abnormal posture that may be difficult to distinguish from other movements, such as 
dystonia and other tic types. Electromyography is an invaluable tool that can aid clinicians in making this important distinction.
Clinical implications. Accurately diagnosing these movements can significantly impact treatment decisions and contribute to 
more homogenous research populations.
(Neurol Neurochir Pol 2019; 53 (5): 315–316)
Gilles de la Tourette syndrome (GTS) is diagnosed in 
individuals who have two or more motor tics and at least one 
phonic tic for at least one year’s duration beginning before 
age 18 [1]. Patients with GTS often have comorbid psychiatric 
problems that, coupled with tics, can lead to substantial im-
pairment. Research has sought to characterize the phenotypic 
variability among those with GTS in order to better understand 
disease mechanisms and identify elements that have the greatest 
impact on quality of life. Accomplishing these goals will allow 
clinicians to more effectively tailor treatment to an individual’s 
specific needs. Szejko et al. have nicely contributed to this effort 
and found that 73.9% of patients with GTS developed dystonic 
tics (DTs) [2].  They also provided a thorough characterization 
of their cohort of 153 patients with DTs. Their attention to 
detail highlights the importance of accurately differentiating 
tics from other movement phenomena, taking an account of 
one’s complete tic repertoire, and correctly identifying types 
of tics, all of which can have a significant impact on treatment.
Tics are stereotypical movements sometimes described as 
semivoluntary or unvoluntary to highlight that they are not 
truly involuntary [3] unlike some other movement pheno-
mena, such as dystonia, which is an involuntary sustained or 
intermittent co-contraction of muscle agonist and antagonists 
resulting in abnormal movements and/or postures [4]. Simple 
tics often have a jerk-like appearance and may be differentiated 
from other jerking movements by their serotyped nature and 
other attributes, including a premonitory urge that resolves 
when the tic is completed. Szejko et al. provide a nice table 
summarizing characteristics to aid in differentiating tics from 
dystonia [2]; however, there are limitations to an approach 
based solely on clinical history and observation as illustrated 
by the fact that 90% of adults and only 37% of children endorse 
a hallmark premonitory urge [5, 6]. Moreover, simple motor 
tics may be misidentified as myoclonus thus leading the clini-
cian to misdiagnosis. EMG is a useful technique that can aid 
in differentiation among these [7] and should be considered 
an integral extension of the neurological examination. Mea-
suring burst duration enables one to categorize tics as clonic 
(< 100ms) or dystonic (> 300ms) [8]. This is a distinction that 
may escape the sensitivity of clinical observation and only 
consistently accomplished with EMG. 
Clinicians should be aware that individuals with GTS may 
have hyperkinetic movements in addition to tics, such as tardive 
chorea or tardive dystonia [9]. Accurately identifying these mo-
vements, which may mimic tics, can have a significant impact 
on treatment decisions, such as whether to increase or decrease 
the dosage of a dopamine antagonist like aripirazole, which is 
commonly used to treat tics [10]. The wrong decision could 
have serious and potentially irreversible consequences given the 
association between these medications and extrapyramidal side 
effects. Once an accurate and specific diagnosis of tics is estab-
lished, appropriate treatments can be pursued. The American 
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Academy of Neurology recently published new guidelines for 
the treatment of tic disorders [11]. Comprehensive Behavioral 
Intervention for Tics (CBIT) is the mainstay of the nonpharma-
cological treatment arm while pharmacological options include 
α-adrenergic agonists, antipsychotics, vesicular monoamine 
transporter-2 inhibitors, and botulinum toxin injections, the last 
of which has particular applicability to those with dystonic tics 
[12].  Botulinum toxin may also be used to treat laryngeal tics [13] 
and has even been shown to reduce the premonitory urge [14].
To effectively treat their patients, clinicians must compile 
a patient’s tic inventory and determine their impact on one’s 
life. This can be accomplished with various rating scales, such 
as the Yale Global Tic Severity Scale (YGTSS) [15, 16]. Szejko 
and colleagues made several interesting observations including 
the average age of onset of DTs 3.7 years after development of 
their first tic suggesting that most individuals do not present 
with DTs [2]. They also showed that the presence of DTs was 
more common in those with more tics overall. Previous reports 
have shown co-occurance of tics and dystonia [17] as well as 
cosegregation of eye-winking tics, frequent eye-blinking and 
blepharosm with a family [18, 19], raising the question of 
a shared mechanism. This idea has since been strengthened 
by identification of a shared mutation within the guanosine 
triphosphate cyclohydrolase I gene (GCHI) in a Danish family 
with dopa-responsive dystonia and GTS [20].
While the first step in evaluating movement disorders is 
accurately identifying the movement phenomenon, clinicians 
must be aware that not all phenomena are ‘pure,’ i.e. tremor 
or tics, but can have characteristics of multiple movement 
phenomena simultaneously, e.g. DTs. Differentiating tics 
from dystonia as well as correctly identifying the type of tic 
is necessary for clinicians to provide appropriate treatment 
options, properly counsel their patients, and to better ho-
mogenize patient populations so that higher quality research 
studies may be conducted.
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